UpStream Bio Inc. Stock Price, News & Analysis

Upstream Bio (NASDAQ:UPB) announced positive top-line results from its Phase 2 VIBRANT trial evaluating verekitug for treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met its primary endpoint with verekitug, dosed every 12 weeks, achieving a significant placebo-adjusted reduction in nasal polyp score of -1.8 (p<0.0001).

The study demonstrated significant improvements in key secondary endpoints, including a -0.8 reduction in nasal congestion score (p=0.0003) and 76% reduction (p=0.03) in need for surgery or systemic corticosteroids. The drug showed a favorable safety profile with no serious adverse events reported. Notably, verekitug's clinical effect appears to meet or exceed that of other biologics in CRSwNP at 24 weeks.

Upstream Bio (NASDAQ:UPB) has scheduled a conference call and webcast for September 2, 2025, at 8:00 a.m. ET to present top-line data from its Phase 2 VIBRANT trial. The study evaluates verekitug, a unique monoclonal antibody targeting TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

The VIBRANT trial (NCT06164704) is a global, randomized, placebo-controlled study where participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The trial's primary endpoint focuses on measuring changes in endoscopic nasal polyp score at Week 24.

Upstream Bio (NASDAQ:UPB) reported Q2 2025 financial results and clinical progress for its lead drug verekitug, the only monoclonal antibody targeting TSLP receptor in development. The company highlighted three key clinical trials: VIBRANT (CRSwNP) with top-line data expected in Q3 2025, VALIANT (severe asthma) with results in Q1 2026, and VENTURE (COPD) which dosed its first patient in July 2025.

Financially, Upstream reported cash position of $393.6 million, expected to fund operations through 2027. Q2 2025 showed a net loss of $40.0 million, up from $14.7 million in Q2 2024, primarily due to increased R&D expenses of $37.9 million and G&A expenses of $7.4 million.

[ "Strong cash position of $393.6 million, funding operations through 2027", "Completed enrollment in Phase 2 severe asthma trial ahead of Q1 2026 data readout", "On track for CRSwNP Phase 2 trial results in Q3 2025", "Expanded clinical program with first COPD patient dosed in July 2025" ]

Upstream Bio (NASDAQ:UPB) has initiated dosing in its Phase 2 clinical trial, VENTURE, evaluating verekitug for Chronic Obstructive Pulmonary Disease (COPD). The trial will assess approximately 670 adults with moderate-to-severe COPD, testing doses of 100 mg every 12 weeks or 400 mg every 24 weeks versus placebo.

This expansion marks verekitug's third indication in development, alongside ongoing Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma. The company has completed enrollment for both existing trials, with data expected in Q3 2025 for CRSwNP and Q1 2026 for severe asthma.

Verekitug, as the only known biologic targeting the TSLP receptor, aims to improve COPD treatment through less frequent dosing and potentially differentiated efficacy compared to existing biologics.

Upstream Bio (UPB) presented translational pharmacology modeling data for verekitug, their novel antibody antagonist targeting the TSLP receptor, at the EAACI Congress. The data demonstrates verekitug's greater potency compared to tezepelumab in treating inflammatory diseases. The modeling shows complete and sustained inhibition of the TSLP/TSLPR complex and predicts greater reduction in FeNO, a lung inflammation biomarker. This superior efficacy is attributed to lower TSLP receptor expression levels and slower protein turnover compared to the ligand. Verekitug is currently in Phase 2 trials for severe asthma, COPD, and CRSwNP, with topline data expected in Q3 2025 for CRSwNP and H1 2026 for severe asthma.

Upstream Bio (Nasdaq: UPB) announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK. The presentation will showcase translational pharmacology modeling data for their drug verekitug, which targets the TSLP receptor for inflammatory diseases, particularly severe respiratory disorders. The data demonstrates verekitug's enhanced potency compared to treatments targeting the TSLP ligand, such as tezepelumab. Dr. Ashish Kalra, VP of Translational Research, will present these findings on June 15, 2025, focusing on the in silico system pharmacology modeling insights that explain the drug's superior potency mechanism.

Upstream Bio (Nasdaq: UPB), a clinical-stage biotech company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET. The presentation will be accessible via live webcast in the Events section of the company's Investors page, with a replay available afterward.

Upstream Bio (Nasdaq: UPB) has appointed Stacy Price as Chief Technology Officer. Price brings over 25 years of experience in technical operations, manufacturing, and product development in biotechnology. In her new role, she will oversee technical operations and product development expansion for verekitug, focusing on CMC processes and drug delivery.

Price previously served as Chief Technology and Manufacturing Officer at Invivyd and Chief Technical Officer at Akouos. She also held senior leadership positions at Ziopharm Oncology, Shire, and Transkaryotic Therapies. Price holds an M.S. in Biochemical Engineering and a B.S. in Chemical Engineering from Tufts University.

Upstream Bio (NASDAQ: UPB) reported its Q1 2025 financial results and accelerated guidance for its clinical programs. The company is developing verekitug, the only monoclonal antibody targeting the TSLP receptor in clinical development. Key updates include: top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps expected in Q3 2025, Phase 2 data for severe asthma now anticipated in H1 2026, and first patient dosing in COPD trial expected mid-2025. Financially, Upstream reported cash position of $431.4M expected to fund operations through 2027. Q1 2025 showed R&D expenses of $25.8M (up from $11.7M in Q1 2024) and a net loss of $27.3M (compared to $10.9M in Q1 2024). The company completed enrollment for its CRSwNP Phase 2 trial in January 2025, with patients receiving 100mg verekitug or placebo every 12 weeks over 24 weeks.